Market News & Trends
Venthera Doses First Patient With Topical Therapy Targeting Genetic Drivers of Rare Vascular Anomalies
BridgeBio Pharma, Inc. and affiliate Venthera recently announced the first subject has been dosed in its Phase 1/2 clinical trial of BBP-681 (also known as…
Cerba Research Announces Time-Saving COVID-19 Exploratory Tools & NGS Advancements
Cerba Research recently announced it has developed two new COVID-19 exploratory tools to enhance clinical research for the development of vaccines and treatments for COVID-19 and other infectious diseases…..
Pacira BioSciences Announces Equity Investment in GeneQuine Biotherapeutics
Pacira BioSciences, Inc. recently announced that the company will lead an equity investment in GeneQuine Biotherapeutics GmbH…..
Relief Therapeutics & Acer Therapeutics Sign Option Agreement for Exclusivity to Negotiate a Collaboration & License Agreement
Relief Therapeutics Holding AG and Acer Therapeutics Inc. recently announced the companies have signed an Option Agreement providing exclusivity for the right to negotiate a potential collaboration and license….
Agenus Enters Clinical Collaboration With Nelum for Zalifrelimab Combination
Agenus Inc. recently announced that it has entered into a clinical collaboration with Nelum Corp. to evaluate the safety and efficacy of zalifrelimab, Agenus’ anti-CTLA-4 antibody….
PromoCell Receives EXCiPACT Certification as Manufacturer of Pharmaceutical Excipients to GMP Standards
PromoCell, one of the leading European manufacturers of human cell culture and cell biology products, has recently announced to have successfully completed a comprehensive EXCiPACT…
Vaxart Announces Additional Preclinical COVID-19 Oral Vaccine Data & Publication
Vaxart, Inc. recently announced additional results from its SARS-CoV-2 Hamster Challenge Study, as well as a peer-reviewed publication in Nature Medicine resulting from a collaboration…
Entasis Therapeutics Announces Sulbactam-Durlobactam Expanded Access Program for Patients in the US
Entasis Therapeutics Holdings Inc. recently announced the availability of an expanded access program (EAP) for sulbactam-durlobactam or SUL-DUR, an investigational drug, for US patients with…
DURECT Corporation Announces First Patient Dosed in Phase 2b AHFIRM Study
DURECT Corporation recently announced it has dosed the first patient in its AHFIRM randomized, double-blind, placebo-controlled, multi-center Phase 2b study to evaluate the safety and efficacy of DUR-928…
Antios Therapeutics Completes Phase 1b Clinical Trial of Active Site Polymerase Inhibitor Nucleotide
Antios Therapeutics, Inc. recently announced it has completed the Phase 1b clinical trial of ATI-2173, an Active Site Polymerase Inhibitor Nucleotide (ASPIN), in patients with…
Ajinomoto Bio-Pharma Services & Humanigen Expand Manufacturing Agreement to Support Fill Finish for Investigational COVID-19 Therapeutic
Ajinomoto Bio-Pharma Services and Humanigen, Inc. recently announced the companies will be expanding their manufacturing agreement for the fill finish supply of lenzilumab, which is…
Stevanato Group Launches After-Sales Service Offering for Technologies & Manufacturing Equipment by Establishing a Global Network
Stevanato Group has launched an updated comprehensive, global after-sales service offering for pharmaceutical customers. Effective from January this year,….
Credence MedSystems Receives Strategic Investment From Novartis
Credence MedSystems recently announced that Novartis has made a strategic investment in the company. The investment will advance ongoing development and scaling of Credence’s innovative drug delivery systems….
Nexelis Acquires GSK Vaccines Clinical Bioanalytical Laboratory
Nexelis, a portfolio company of Ampersand Capital Partners, and a leading provider of advanced assay development and laboratory testing services in the infectious, oncologic, and metabolic diseases fields, has signed an asset purchase agreement with GSK to….
ViGeneron Announces Research Collaboration With Daiichi Sankyo to Evaluate Novel Ophthalmic Gene Therapy
ViGeneron GmbH recently announced a research collaboration to utilize its novel engineered adeno-associated virus (vgAAV) vectors with Daiichi Sankyo Company, Limited for delivering….
Molecular Templates Announces FDA Acceptance of IND Application for a PD-L1-Targeted Engineered Toxin Body Enabled With Proprietary Antigen Seeding Technology
Molecular Templates, Inc. recently announced the US FDA has accepted its Investigational New Drug (IND) application for MT-6402, a next-generation ETB targeting PD-L1 that is enabled with….
Clene Nanomedicine Receives Patent Notice of Allowance for using Gold Nanocrystals for Treating MS
Clene Inc. recently announced its wholly owned subsidiary Clene Nanomedicine, Inc., a clinical-stage biopharmaceutical company, was issued a Notice of Allowance from the US Patent and Trademark Office (USPTO) for its invention for….
Cognate BioServices & Its Gene Therapy Division Cobra Biologics Announce Major Expansion
Cobra Biologics, the gene therapy division of the Cognate BioServices’ group, recently announced a multi-phase augmentation of its plasmid DNA services as a continuation of…
Cocrystal Pharma Announces Further Development of Influenza A/B Antiviral Compounds by Merck Under Exclusive Worldwide License & Collaboration Agreement
Cocrystal Pharma, Inc. recently announced it has completed all research obligations under the Merck exclusive worldwide license and collaboration agreement, and that Merck is now…
Neuropathix Announces Publication of Its Global PCT Patent for a Novel Hops-Inspired Neuroprotectant
Neuropathix, Inc. recently announced the publication of its global WIPO/PCT Patent WO 2020/ 264324 – Use of Certain Phosphatidylcholines Containing Long Chain Polyunsaturated Fatty Acids…
